Fervent Synergies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Fervent Synergies şirketinin toplam hissedar öz sermayesi ₹354.9M ve toplam borcu ₹0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹356.2M ve ₹1.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

₹0

Borç

Faiz karşılama oranı	n/a
Nakit	₹1.12m
Eşitlik	₹354.85m
Toplam yükümlülükler	₹1.37m
Toplam varlıklar	₹356.22m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 533896 'nin kısa vadeli varlıkları ( ₹281.2M ) kısa vadeli yükümlülüklerini ( ₹310.0K ) aşıyor.

Uzun Vadeli Yükümlülükler: 533896 şirketinin kısa vadeli varlıkları ( ₹281.2M ) uzun vadeli yükümlülüklerini ( ₹1.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 533896 borçsuzdur.

Borcun Azaltılması: 533896 son 5 yıldır borcu bulunmamaktadır.

Borç Kapsamı: 533896 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 533896 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Fervent Synergies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Second quarter 2025 earnings released: EPS: ₹0.01 (vs ₹0.03 in 2Q 2024)

Fervent Synergies Limited to Report Q2, 2025 Results on Oct 24, 2024

New major risk - Share price stability

First quarter 2025 earnings released: EPS: ₹0.02 (vs ₹0.03 in 1Q 2024)

New minor risk - Share price stability

Fervent Synergies Limited announced that it has received INR 50 million in funding from Blue Berry Securities Pvt Ltd and other investors

Fervent Synergies Limited to Report Q1, 2025 Results on Aug 08, 2024

Fervent Synergies Limited, Annual General Meeting, Jul 11, 2024

Full year 2024 earnings released: ₹4.28 loss per share (vs ₹0.077 profit in FY 2023)

Fervent Synergies Limited Appoints Nehal Bharat Mehta as Company Secretary and Compliance Officer

Fervent Synergies Limited Announces Resignation of Pooja Sanghavi as Company Secretary / Compliance Officer

Third quarter 2024 earnings released

First half 2024 earnings released: EPS: ₹0.06 (vs ₹0.04 in 1H 2023)

Fervent Synergies Limited to Report Q2, 2024 Results on Nov 02, 2023

New major risk - Share price stability

Fervent Synergies Limited, Annual General Meeting, Sep 28, 2023

First quarter 2024 earnings released: EPS: ₹0.03 (vs ₹0.02 in 1Q 2023)

Fervent Synergies Limited to Report Q1, 2024 Results on Aug 03, 2023

Full year 2023 earnings released: EPS: ₹0.08 (vs ₹0.079 loss in FY 2022)

Third quarter 2023 earnings released: EPS: ₹0.05 (vs ₹0.01 loss in 3Q 2022)

Fervent Synergies Limited to Report Q3, 2023 Results on Feb 02, 2023

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹0.02 (vs ₹0.01 in 2Q 2022)

Fervent Synergies Limited to Report Q2, 2023 Results on Oct 20, 2022

First quarter 2023 earnings released

Fervent Synergies Limited, Annual General Meeting, Sep 22, 2022

Fervent Synergies Limited to Report Q1, 2023 Results on Aug 04, 2022

Full year 2022 earnings released: ₹0.08 loss per share (vs ₹0.058 profit in FY 2021)

Fervent Synergies Limited to Report Fiscal Year 2022 Results on May 12, 2022

Fervent Pharmaceuticals Commences Virtual at Home Phase 2 Clinical Trial of a Peri- and Post-Menopausal Therapy for Treating Hot Flashes and Night Sweats

Insufficient new directors

Second quarter 2022 earnings released: EPS ₹0.01 (vs ₹0.009 in 2Q 2021)

Full year 2021 earnings released: EPS ₹0.058 (vs ₹0.079 in FY 2020)

Full year 2021 earnings released: EPS ₹0.06 (vs ₹0.079 in FY 2020)

Third quarter 2021 earnings released: EPS ₹0.03 (vs ₹0.03 loss in 3Q 2020)

Fervent Synergies Limited to Report Q3, 2021 Results on Jan 28, 2021

New 90-day high: ₹11.52

New 90-day low: ₹8.19

Fervent Synergies Limited, Annual General Meeting, Dec 03, 2020

First half earnings released

New 90-day low: ₹8.36

New 90-day low: ₹9.00

First quarter earnings released

Fervent Synergies Limited to Report Q1, 2021 Results on Jul 30, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin